Colchicine in Patients with Chronic Coronary Disease

20201,991 citationsJournal Articlebronze Open Access

Authors

Stefan M. Nidorf · Sir Charles Gairdner Hospital

Aernoud T.L. Fiolet · Netherlands Heart Institute

Arend Mosterd · Oklahoma State University Center for Health Sciences

John W. Eikelboom · McMaster University

Astrid Schut

Tjerk S.J. Opstal · Radboud University Nijmegen

Salem H.K. The · Treant Zorggroep

Abstract

In a randomized trial involving patients with chronic coronary disease, the risk of cardiovascular events was significantly lower among those who received 0.5 mg of colchicine once daily than among those who received placebo. (Funded by the National Health Medical Research Council of Australia and others; LoDoCo2 Australian New Zealand Clinical Trials Registry number, ACTRN12614000093684.).

Topics & Keywords

Inflammasome and immune disorders Atherosclerosis and Cardiovascular Diseases Gout, Hyperuricemia, Uric Acid

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 19, pp. 1838-1847

DOI: 10.1056/nejmoa2021372

Field-Weighted Citation Impact: 85.47